Phathom Pharmaceuticals, Inc.
PHATNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $628.10M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.52$18.31
- Volume (live)
- -
- Avg. volume (3M)
- 1.37M
Phathom Pharmaceuticals (PHAT) Stock Price & Financial Analysis
Phathom Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $6.90 - $7.57 |
|---|---|
| 52-Week High | $18.31 |
| 52-Week Low | $6.52 |
| Open | $7.51 |
| Volume (last close) | 1.25M |
| Average Volume (3M) | 1.37M |
| Revenue (TTM) | 239.66M |
|---|---|
| Net Income (TTM) | -99.07M |
| Free Cash Flow (TTM) | -36.71M |
| EPS (TTM) | −$1.27 |
| Profit Margin | -41.34% |
| Operating Margin | -16.96% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 628.10M |
|---|---|
| Shares Outstanding | 83.75M |
| Price to Sales (P/S) | 2.62 |
| Price to Book (P/B) | -1.82 |
| EV/EBITDA | -17.39 |
| 50-Day MA | $8.20 |
|---|---|
| 200-Day MA | $11.01 |
| 1-Year Change | −42.13% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Phathom Pharmaceuticals at a Glance
As of the Oct 16, 2026 close, Phathom Pharmaceuticals (PHAT) has a market capitalization of $628.10M. The stock trades at 2.6× sales. Over the trailing twelve months it lost $99.07M on revenue of $239.66M and burned $36.71M of free cash flow. Revenue grew 110.2% year over year.
As of its latest reported balance sheet, it holds $182.48M in cash and securities against $165.26M of debt, a net cash position of $17.22M.
Phathom Pharmaceuticals does not currently pay a dividend.
The share price is down 42.1% over the past year. At $6.92 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $6.52 to $18.31, below its 200-day moving average of $11.01.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $19.29, 178.8% above the Oct 16, 2026 close.
Frequently Asked Questions About Phathom Pharmaceuticals
What is the current stock price for PHAT?
As of the Oct 16, 2026 close, PHAT stock trades at $6.92. The 52-week range is $6.52–$18.31, with a day range of $6.90–$7.57.
What is the P/E ratio for PHAT?
The P/E ratio (Price-to-Earnings) for PHAT is shown in the Key Statistics section. This valuation metric helps compare Phathom Pharmaceuticals, Inc. to industry peers.
Does PHAT pay dividends?
Phathom Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PHAT?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for PHAT is Buy. The average 12-month price target is $19.29, a 178.8% upside from the Oct 16, 2026 close of $6.92.
What is the market cap of PHAT?
As of the Oct 16, 2026 close, Phathom Pharmaceuticals's market capitalization is $579.5M, classifying it as a small-cap company. Phathom Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.